ArticleFrontiers in neurology
Real-world use and impact of direct oral anticoagulants among atrial fibrillation patients with cardioembolic stroke.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Atrial fibrillation (AF) is a primary cause of cardioembolic stroke (CES). Non-adherence to direct oral anticoagulants (DOACs) remains a major health policy issue. This study aimed to investigate real-world DOAC usage among AF patients presenting with stroke and to evaluate the impact of prior DOAC therapy on stroke severity. Methods: This retrospective study analyzed data on DOAC usage from CES patients with AF admitted to the two largest Latvian university hospitals between January 2022 and December 2024. We further compared patients' characteristics receiving prior DOAC therapy and those who were not, confirming our findings by a propensity-matched analysis of both groups. Results: Of the 2,610 CES patients enrolled, the largest subgroup (43.4%) consisted of individuals with known AF who were not on anticoagulation therapy before the stroke event. A propensity-matched analysis adjusted for demographics, arrival time, AF type, HAS-BLED, and CHA Conclusion: Non-adherence to DOACs is a substantial contributor to the CES burden. Prior DOAC use is associated with significantly reduced initial stroke severity. Patients with CES while on DOACs exhibited substantially larger left atria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.